Literature DB >> 23344789

Discriminating radiation necrosis from tumor progression in gliomas: a systematic review what is the best imaging modality?

Ashish H Shah1, Brian Snelling, Amade Bregy, Payal R Patel, Danoushka Tememe, Rita Bhatia, Evelyn Sklar, Ricardo J Komotar.   

Abstract

Differentiating post radiation necrosis from progression of glioma and pseudoprogression poses a diagnostic conundrum for many clinicians. As radiation therapy and temozolomide chemotherapy have become the mainstay of treatment for higher-grade gliomas, radiation necrosis and post treatment changes such as pseudoprogression have become a more relevant clinical problem for neurosurgeons and neurooncologists. Due to their radiological similarity to tumor progression, accurate recognition of these findings remains paramount given their vastly different treatment regimens and prognoses. However, no consensus has been reached on the optimal technique to discriminate between these two lesions. In order to clarify the types of imaging modalities for recurrent enhancing lesions, we conducted a systematic review of case reports, case series, and prospective studies to increase our current understanding of the imaging options for these common lesions and their efficacy. In particular, we were interested in distinguishing radiation necrosis from true tumor progression. A PubMed search was performed to include all relevant studies where the imaging was used to differentiate between radiation necrosis and recurrent gliomas with post-radiation enhancing lesions. After screening for certain parameters in our study, seventeen articles with 435 patients were included in our analysis including 10 retrospective and 7 prospective studies. The average time from the end of radiation therapy to the onset of a recurrent enhancing lesion was 13.2 months. The most sensitive and specific imaging modality was SPECT with a sensitivity of 87.6 % and specificity of 97.8 %. Based on our review, we conclude that certain imaging modalities may be preferred over other less sensitive/specific techniques. Overall, tests such as SPECT may be preferable in differentiating TP (tumor progression) from RN (radiation necrosis) due to its high specificity, while nonspecific imaging such as conventional MRI is not ideal.

Entities:  

Mesh:

Year:  2013        PMID: 23344789     DOI: 10.1007/s11060-013-1059-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  55 in total

1.  Support vector machine multiparametric MRI identification of pseudoprogression from tumor recurrence in patients with resected glioblastoma.

Authors:  Xintao Hu; Kelvin K Wong; Geoffrey S Young; Lei Guo; Stephen T Wong
Journal:  J Magn Reson Imaging       Date:  2011-02       Impact factor: 4.813

2.  Radiation necrosis versus glioma recurrence: conventional MR imaging clues to diagnosis.

Authors:  Mark E Mullins; Glenn D Barest; Pamela W Schaefer; Fred H Hochberg; R Gilberto Gonzalez; Michael H Lev
Journal:  AJNR Am J Neuroradiol       Date:  2005-09       Impact factor: 3.825

Review 3.  Imaging of gliomas.

Authors:  T N Byrne
Journal:  Semin Oncol       Date:  1994-04       Impact factor: 4.929

4.  Gliomas: Histogram analysis of apparent diffusion coefficient maps with standard- or high-b-value diffusion-weighted MR imaging--correlation with tumor grade.

Authors:  Yusuhn Kang; Seung Hong Choi; Young-Jae Kim; Kwang Gi Kim; Chul-Ho Sohn; Ji-Hoon Kim; Tae Jin Yun; Kee-Hyun Chang
Journal:  Radiology       Date:  2011-10-03       Impact factor: 11.105

5.  Differentiation between recurrent brain tumour and post-radiation necrosis: the value of 201Tl SPET versus 18F-FDG PET using a dual-headed coincidence camera--a pilot study.

Authors:  M Stokkel; H Stevens; M Taphoorn; P Van Rijk
Journal:  Nucl Med Commun       Date:  1999-05       Impact factor: 1.690

6.  Treatment of radiation-induced nervous system injury with heparin and warfarin.

Authors:  M J Glantz; P C Burger; A H Friedman; R A Radtke; E W Massey; S C Schold
Journal:  Neurology       Date:  1994-11       Impact factor: 9.910

7.  Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected].

Authors:  Michael H Lev; Yelda Ozsunar; John W Henson; Amjad A Rasheed; Glenn D Barest; Griffith R Harsh; Markus M Fitzek; E Antonio Chiocca; James D Rabinov; Andrew N Csavoy; Bruce R Rosen; Fred H Hochberg; Pamela W Schaefer; R Gilberto Gonzalez
Journal:  AJNR Am J Neuroradiol       Date:  2004-02       Impact factor: 3.825

8.  Diagnosis of recurrent brain tumor: value of 201Tl SPECT vs 18F-fluorodeoxyglucose PET.

Authors:  D Kahn; K A Follett; D L Bushnell; M A Nathan; J G Piper; M Madsen; P T Kirchner
Journal:  AJR Am J Roentgenol       Date:  1994-12       Impact factor: 3.959

9.  Hyperbaric oxygen therapy for radiation-induced brain injury in children.

Authors:  P J Chuba; P Aronin; K Bhambhani; M Eichenhorn; L Zamarano; P Cianci; M Muhlbauer; A T Porter; J Fontanesi
Journal:  Cancer       Date:  1997-11-15       Impact factor: 6.860

Review 10.  The morphologic effects of radiation administered therapeutically for intracranial gliomas: a postmortem study of 25 cases.

Authors:  P C Burger; M S Mahley; L Dudka; F S Vogel
Journal:  Cancer       Date:  1979-10       Impact factor: 6.860

View more
  39 in total

1.  Diagnostic Accuracy of PET, SPECT, and Arterial Spin-Labeling in Differentiating Tumor Recurrence from Necrosis in Cerebral Metastasis after Stereotactic Radiosurgery.

Authors:  G Lai; A Mahadevan; D Hackney; P C Warnke; F Nigim; E Kasper; E T Wong; B S Carter; C C Chen
Journal:  AJNR Am J Neuroradiol       Date:  2015-10-01       Impact factor: 3.825

2.  Application of diffusion-weighted magnetic resonance imaging to predict the intracranial metastatic tumor response to gamma knife radiosurgery.

Authors:  Cheng-Chia Lee; Max Wintermark; Zhiyuan Xu; Chun-Po Yen; David Schlesinger; Jason P Sheehan
Journal:  J Neurooncol       Date:  2014-04-24       Impact factor: 4.130

3.  The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma.

Authors:  Norbert Galldiks; Gabriele Stoffels; Christian Filss; Marion Rapp; Tobias Blau; Caroline Tscherpel; Garry Ceccon; Veronika Dunkl; Martin Weinzierl; Michael Stoffel; Michael Sabel; Gereon R Fink; Nadim J Shah; Karl-Josef Langen
Journal:  Neuro Oncol       Date:  2015-05-24       Impact factor: 12.300

4.  Perfusion-metabolism coupling in recurrent gliomas: a prospective validation study with 13N-ammonia and 18F-fluorodeoxyglucose PET/CT.

Authors:  Bangkim Chandra Khangembam; Sellam Karunanithi; Punit Sharma; Sudhir Suman Kc; Rajeev Kumar; Pramod Kumar Julka; Rakesh Kumar; Chandrasekhar Bal
Journal:  Neuroradiology       Date:  2014-07-03       Impact factor: 2.804

Review 5.  MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis.

Authors:  Praneil Patel; Hediyeh Baradaran; Diana Delgado; Gulce Askin; Paul Christos; Apostolos John Tsiouris; Ajay Gupta
Journal:  Neuro Oncol       Date:  2016-08-08       Impact factor: 12.300

Review 6.  Current Clinical Brain Tumor Imaging.

Authors:  Javier E Villanueva-Meyer; Marc C Mabray; Soonmee Cha
Journal:  Neurosurgery       Date:  2017-09-01       Impact factor: 4.654

Review 7.  Unyielding progress: recent advances in the treatment of central nervous system neoplasms with radiosurgery and radiation therapy.

Authors:  Dale Ding; Chun-Po Yen; Robert M Starke; Cheng-Chia Lee; Jason P Sheehan
Journal:  J Neurooncol       Date:  2014-08-14       Impact factor: 4.130

8.  Combined iron oxide nanoparticle ferumoxytol and gadolinium contrast enhanced MRI define glioblastoma pseudoprogression.

Authors:  Ramon F Barajas; Bronwyn E Hamilton; Daniel Schwartz; Heather L McConnell; David R Pettersson; Andrea Horvath; Laszlo Szidonya; Csanad G Varallyay; Jenny Firkins; Jerry J Jaboin; Charlotte D Kubicky; Ahmed M Raslan; Aclan Dogan; Justin S Cetas; Jeremy Ciporen; Seunggu J Han; Prakash Ambady; Leslie L Muldoon; Randy Woltjer; William D Rooney; Edward A Neuwelt
Journal:  Neuro Oncol       Date:  2019-03-18       Impact factor: 12.300

Review 9.  Post-treatment imaging changes in primary brain tumors.

Authors:  Barbara J O'Brien; Rivka R Colen
Journal:  Curr Oncol Rep       Date:  2014       Impact factor: 5.075

10.  Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence.

Authors:  Alexander Radbruch; Joachim Fladt; Philipp Kickingereder; Benedikt Wiestler; Martha Nowosielski; Philipp Bäumer; Heinz-Peter Schlemmer; Antje Wick; Sabine Heiland; Wolfgang Wick; Martin Bendszus
Journal:  Neuro Oncol       Date:  2014-07-18       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.